Exploiting these signaling pathways has showed promising results in cancer therapy: for example, PD-L1 increases PI3K/AKT expression in colorectal cancer cells [325]; as a result, PD-L1 targeted therapy has been developed in the form of Nivolumab [326,327,328]. This evidence concerns the gene PIK3CA and cancer.